Organogenesis (ORGO) Stock Forecast, Price Target & Predictions
ORGO Stock Forecast
Organogenesis stock forecast is as follows: an average price target of $5.00 (represents a 77.94% upside from ORGO’s last price of $2.81) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ORGO Price Target
The average price target for Organogenesis (ORGO) is $5.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 77.94% upside from ORGO's last price of $2.81.
ORGO Analyst Ratings
According to 3 Wall Street analysts, Organogenesis's rating consensus is 'Buy'. The analyst rating breakdown for ORGO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Organogenesis Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | Brooks O'Neil | Lake Street | $5.00 | $2.64 | 89.39% | 77.94% |
The latest Organogenesis stock forecast, released on Jun 28, 2024 by Brooks O'Neil from Lake Street, set a price target of $5.00, which represents a 89.39% increase from the stock price at the time of the forecast ($2.64), and a 77.94% increase from ORGO last price ($2.81).
Organogenesis Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $5.00 | $5.00 |
| Last Closing Price | $2.81 | $2.81 | $2.81 |
| Upside/Downside | -100.00% | 77.94% | 77.94% |
In the current month, the average price target of Organogenesis stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Organogenesis's last price of $2.81. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 28, 2024 | Lake Street | - | Buy | Initialise |
| Dec 27, 2023 | BTIG | Buy | Buy | Hold |
| May 24, 2023 | WestPark Capital | - | Hold | Initialise |
| May 24, 2023 | BTIG | - | Buy | Upgrade |
Organogenesis's last stock rating was published by Lake Street on Jun 28, 2024. The company Initialise its ORGO rating from "null" to "Buy".
Organogenesis Financial Forecast
Organogenesis Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $108.53M | $117.32M | $107.64M | $115.52M | $116.86M | - | $98.12M | $128.56M | $113.75M | $123.20M | $102.55M | $106.81M | $100.80M | $68.96M | $61.73M | $74.64M | $64.27M | $64.95M | $57.12M |
| Avg Forecast | $130.30M | $117.51M | $134.88M | $114.65M | $104.59M | $109.48M | $121.30M | $101.06M | $109.06M | $111.43M | $115.09M | $95.52M | $122.40M | $120.85M | $120.91M | $95.95M | $124.71M | $112.24M | $105.95M | $86.09M | $105.25M | $71.95M | $58.82M | $60.90M | $70.40M | $62.97M | $60.35M | $52.60M |
| High Forecast | $133.79M | $120.66M | $138.49M | $117.72M | $107.39M | $112.41M | $124.55M | $103.77M | $111.98M | $114.41M | $118.17M | $98.07M | $125.68M | $124.09M | $120.91M | $96.81M | $125.83M | $113.24M | $106.90M | $86.86M | $106.19M | $72.59M | $59.35M | $61.45M | $71.03M | $63.53M | $60.89M | $53.07M |
| Low Forecast | $127.72M | $115.18M | $132.21M | $112.38M | $102.52M | $107.31M | $118.90M | $99.06M | $106.89M | $109.22M | $112.81M | $93.62M | $119.97M | $118.46M | $120.91M | $95.09M | $123.60M | $111.23M | $105.00M | $85.32M | $104.31M | $71.31M | $58.30M | $60.35M | $69.77M | $62.40M | $59.81M | $52.13M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.97% | 1.02% | 1.13% | 0.94% | 0.97% | - | 1.02% | 1.03% | 1.01% | 1.16% | 1.19% | 1.01% | 1.40% | 1.17% | 1.01% | 1.06% | 1.02% | 1.08% | 1.09% |
Organogenesis's average Quarter revenue forecast for Dec 23 based on 1 analysts is $109.06M, with a low forecast of $106.89M, and a high forecast of $111.98M. ORGO's average Quarter revenue forecast represents a 0.48% increase compared to the company's last Quarter revenue of $108.53M (Sep 23).
Organogenesis EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | $8.05M | $13.23M | $1.89M | $8.72M | $6.29M | - | $5.28M | $25.27M | $19.09M | $27.34M | $15.99M | $23.98M | $25.82M | $-520.00K | $-12.05M | $600.00K | $-5.95M | $-5.08M | $-11.43M |
| Avg Forecast | $10.41M | $9.39M | $10.77M | $9.16M | $8.35M | $8.74M | $9.69M | $8.07M | $8.71M | $8.90M | $9.19M | $7.63M | $9.78M | $11.55M | $9.66M | $9.45M | $9.96M | $10.50M | $20.32M | $79.18M | $8.41M | $5.75M | $-829.64K | $-9.27M | $5.62M | $-6.40M | $-5.50M | $-5.72M |
| High Forecast | $10.69M | $9.64M | $11.06M | $9.40M | $8.58M | $8.98M | $9.95M | $8.29M | $8.94M | $9.14M | $9.44M | $7.83M | $10.04M | $13.86M | $9.66M | $11.34M | $10.05M | $12.60M | $24.38M | $95.01M | $8.48M | $5.80M | $-663.71K | $-7.41M | $5.67M | $-5.12M | $-4.40M | $-4.57M |
| Low Forecast | $10.20M | $9.20M | $10.56M | $8.98M | $8.19M | $8.57M | $9.50M | $7.91M | $8.54M | $8.72M | $9.01M | $7.48M | $9.58M | $9.24M | $9.66M | $7.56M | $9.87M | $8.40M | $16.25M | $63.34M | $8.33M | $5.70M | $-995.56K | $-11.12M | $5.57M | $-7.68M | $-6.61M | $-6.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | 1.44% | 0.25% | 0.89% | 0.54% | - | 0.56% | 2.54% | 1.82% | 1.35% | 0.20% | 2.85% | 4.49% | 0.63% | 1.30% | 0.11% | 0.93% | 0.92% | 2.00% |
1 analysts predict ORGO's average Quarter EBITDA for Dec 23 to be $8.71M, with a high of $8.94M and a low of $8.54M. This is 8.20% upper than Organogenesis's previous annual EBITDA (Sep 23) of $8.05M.
Organogenesis Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | $12.11M | $5.32M | $-2.97M | $7.49M | $215.00K | - | $87.00K | $51.70M | $12.58M | $20.69M | $9.94M | $18.49M | $20.93M | $-5.17M | $-16.31M | $-4.40M | $-10.74M | $-9.65M | $-15.67M |
| Avg Forecast | $-1.33M | $-1.33M | $-1.33M | $-1.33M | $-3.09M | $-2.65M | $662.87K | $-3.09M | $1.11M | $1.48M | $4.10M | $-2.62M | $6.63M | $7.61M | $10.67M | $155.54K | $10.92M | $6.92M | $15.37M | $49.22M | $16.22M | $-10.55M | $-8.24M | $-12.55M | $-12.20M | $-11.57M | $-10.45M | $-7.83M |
| High Forecast | $-1.29M | $-1.29M | $-1.29M | $-1.29M | $-3.01M | $-2.58M | $685.93K | $-3.01M | $1.15M | $1.53M | $4.24M | $-2.56M | $6.86M | $9.13M | $10.67M | $186.65K | $11.05M | $8.30M | $18.44M | $59.06M | $16.41M | $-10.43M | $-6.59M | $-10.04M | $-12.05M | $-9.25M | $-8.36M | $-6.27M |
| Low Forecast | $-1.37M | $-1.37M | $-1.37M | $-1.37M | $-3.20M | $-2.74M | $645.78K | $-3.20M | $1.08M | $1.44M | $3.99M | $-2.72M | $6.46M | $6.09M | $10.67M | $124.43K | $10.79M | $5.53M | $12.30M | $39.37M | $16.03M | $-10.67M | $-9.89M | $-15.06M | $-12.34M | $-13.88M | $-12.54M | $-9.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | 8.19% | 1.30% | 1.13% | 1.13% | 0.03% | - | 0.56% | 4.73% | 1.82% | 1.35% | 0.20% | 1.14% | -1.98% | 0.63% | 1.30% | 0.36% | 0.93% | 0.92% | 2.00% |
Organogenesis's average Quarter net income forecast for Dec 23 is $1.11M, with a range of $1.08M to $1.15M. ORGO's average Quarter net income forecast represents a -90.84% decrease compared to the company's last Quarter net income of $12.11M (Sep 23).
Organogenesis SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | $64.22M | $70.32M | $73.83M | $68.29M | $79.33M | - | $63.58M | $67.25M | $62.37M | $62.35M | $58.23M | $53.22M | $51.15M | $46.50M | $52.61M | $52.37M | $49.48M | $48.96M | $48.89M |
| Avg Forecast | $80.54M | $72.63M | $83.37M | $70.87M | $64.65M | $67.67M | $74.98M | $62.47M | $67.41M | $68.87M | $71.14M | $59.04M | $75.66M | $37.73M | $74.74M | $59.30M | $77.09M | $34.30M | $46.32M | $53.21M | $65.06M | $44.47M | $36.36M | $40.47M | $43.51M | $53.28M | $53.04M | $24.45M |
| High Forecast | $82.69M | $74.58M | $85.60M | $72.76M | $66.38M | $69.48M | $76.98M | $64.14M | $69.21M | $70.72M | $73.04M | $60.62M | $77.68M | $45.28M | $74.74M | $59.84M | $77.78M | $41.16M | $55.59M | $53.69M | $65.64M | $44.87M | $36.68M | $48.57M | $43.90M | $63.94M | $63.64M | $29.34M |
| Low Forecast | $78.94M | $71.19M | $81.72M | $69.46M | $63.37M | $66.33M | $73.49M | $61.23M | $66.07M | $67.51M | $69.73M | $57.87M | $74.16M | $30.19M | $74.74M | $58.77M | $76.40M | $27.44M | $37.06M | $52.73M | $64.47M | $44.07M | $36.03M | $32.38M | $43.12M | $42.62M | $42.43M | $19.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.93% | 0.99% | 1.25% | 0.90% | 2.10% | - | 1.07% | 0.87% | 1.82% | 1.35% | 1.09% | 0.82% | 1.15% | 1.28% | 1.30% | 1.20% | 0.93% | 0.92% | 2.00% |
Organogenesis's average Quarter SG&A projection for Dec 23 is $67.41M, based on 1 Wall Street analysts, with a range of $66.07M to $69.21M. The forecast indicates a 4.96% rise compared to ORGO last annual SG&A of $64.22M (Sep 23).
Organogenesis EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | $0.09 | $0.04 | $-0.02 | $0.06 | - | - | - | $0.40 | $0.10 | $0.16 | $0.08 | $0.16 | $0.20 | $-0.05 | $-0.16 | $-0.04 | $-0.12 | $-0.11 | $-0.17 |
| Avg Forecast | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $0.01 | $-0.02 | $0.01 | $0.01 | $0.03 | $-0.02 | $0.05 | $0.06 | $0.08 | $0.05 | $0.08 | $0.06 | $0.06 | $-0.02 | $0.12 | $-0.08 | $-0.23 | $-0.13 | $-0.09 | $-0.13 | $-0.13 | $-0.11 |
| High Forecast | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $0.01 | $-0.02 | $0.01 | $0.01 | $0.03 | $-0.02 | $0.05 | $0.06 | $0.08 | $0.05 | $0.08 | $0.06 | $0.06 | $-0.02 | $0.12 | $-0.08 | $-0.22 | $-0.13 | $-0.09 | $-0.13 | $-0.13 | $-0.11 |
| Low Forecast | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | - | $-0.02 | $0.01 | $0.01 | $0.03 | $-0.02 | $0.05 | $0.06 | $0.08 | $0.05 | $0.08 | $0.06 | $0.06 | $-0.02 | $0.12 | $-0.08 | $-0.23 | $-0.13 | $-0.09 | $-0.13 | $-0.13 | $-0.11 |
| Surprise % | - | - | - | - | - | - | - | - | - | 8.27% | 1.29% | 1.14% | 1.20% | 0.03% | - | 0.01% | 4.83% | 1.60% | 2.78% | -4.32% | 1.30% | -2.50% | 0.22% | 1.20% | 0.43% | 0.95% | 0.85% | 1.59% |
According to 1 Wall Street analysts, Organogenesis's projected average Quarter EPS for Dec 23 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a -90.93% decrease compared to ORGO previous annual EPS of $0.09 (Sep 23).
Organogenesis Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DVAX | Dynavax | $11.17 | $24.50 | 119.34% | Buy |
| ORGO | Organogenesis | $2.81 | $5.00 | 77.94% | Buy |
| LFCR | Lifecore Biomedical | $5.18 | $8.00 | 54.44% | Buy |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| ITCI | Intra-Cellular Therapies | $75.38 | $94.00 | 24.70% | Buy |
| NBIX | Neurocrine Biosciences | $122.25 | $146.60 | 19.92% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| ALIM | Alimera Sciences | $5.54 | $5.75 | 3.79% | Hold |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| GHSI | Guardion Health Sciences | $9.91 | $0.01 | -99.90% | Buy |
ORGO Forecast FAQ
Is Organogenesis a good buy?
Yes, according to 3 Wall Street analysts, Organogenesis (ORGO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of ORGO's total ratings.
What is ORGO's price target?
Organogenesis (ORGO) average price target is $5 with a range of $5 to $5, implying a 77.94% from its last price of $2.81. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Organogenesis stock go up soon?
According to Wall Street analysts' prediction for ORGO stock, the company can go up by 77.94% (from the last price of $2.81 to the average price target of $5), up by 77.94% based on the highest stock price target, and up by 77.94% based on the lowest stock price target.
Can Organogenesis stock reach $4?
ORGO's average twelve months analyst stock price target of $5 supports the claim that Organogenesis can reach $4 in the near future.
What are Organogenesis's analysts' financial forecasts?
Organogenesis's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $436.43M (high $448.11M, low $427.78M), average EBITDA is $34.86M (high $35.79M, low $34.17M), average net income is $-8.175M (high $-7.924M, low $-8.5M), average SG&A $269.76M (high $276.98M, low $264.41M), and average EPS is $-0.0617 (high $-0.0598, low $-0.0641). ORGO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $497.34M (high $510.65M, low $487.48M), average EBITDA is $39.72M (high $40.78M, low $38.93M), average net income is $-5.303M (high $-5.166M, low $-5.487M), average SG&A $307.41M (high $315.63M, low $301.31M), and average EPS is $-0.04 (high $-0.039, low $-0.0414).
Did the ORGO's actual financial results beat the analysts' financial forecasts?
Based on Organogenesis's last annual report (Dec 2023), the company's revenue was $433.14M, beating the average analysts forecast of $431.09M by 0.48%. Apple's EBITDA was $12.52M, missing the average prediction of $34.43M by -63.62%. The company's net income was $15.84M, beating the average estimation of $4.06M by 290.22%. Apple's SG&A was $269.75M, beating the average forecast of $266.46M by 1.24%. Lastly, the company's EPS was $0.0001, missing the average prediction of $0.0306 by -99.67%. In terms of the last quarterly report (Sep 2023), Organogenesis's revenue was $108.53M, missing the average analysts' forecast of $111.43M by -2.60%. The company's EBITDA was $8.05M, missing the average prediction of $8.9M by -9.55%. Organogenesis's net income was $12.11M, beating the average estimation of $1.48M by 719.04%. The company's SG&A was $64.22M, missing the average forecast of $68.87M by -6.75%. Lastly, the company's EPS was $0.0922, beating the average prediction of $0.0112 by 726.91%